Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Novel Transcriptional Factors Regulating Cancer Stemness
share announcement

Novel Transcriptional Factors Regulating Cancer Stemness

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 2351

Special Issue Editor

Dr. Mingyao Ying

E-Mail Website
Guest Editor
Department of Neurology, Hugo W. Moser Research Institute at Kennedy Krieger and Johns Hopkins School of Medicine, 707 North Broadway, Baltimore, MD 21205, USA
Interests: cancer stem cell; brain tumor; transcription factors; targeted therapy

Special Issue Information

Dear Colleagues,

Cancer stemness, referring to the stem-cell-like phenotypes of cancer cells, plays an essential role in tumor initiation, progression, and metastasis, as well as various malignant phenotypes, including therapeutic resistance, angiogenesis, and immune evasion.  Preclinical evidence has supported that targeting cancer stemness may be considered a key element in cancer treatment for more effective inhibition of tumor growth and recurrence.

Cancer stemness is regulated by a transcriptional network relying on transcription factors to transfer and amplify oncogenic signals. A more comprehensive understanding of transcription factors in this network will facilitate the development of therapeutic strategies targeting cancer stemness. This Special Issue will publish novel discoveries of transcription factors regulating cancer stemness, and their associated molecular mechanisms and potential targeted strategies.  

This Special Issue will highlight the latest discoveries in the field of transcriptional regulation of cancer stemness, with a particular focus on novel mechanistic insights and therapeutic development.

Dr. Mingyao Ying
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer stem-like cells
  • stemness
  • tumor heterogeneity
  • transcriptional regulation
  • epigenetics
  • targeted therapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

19 pages, 59366 KiB  
Article
Glioma-Stem-Cell-Derived Exosomes Remodeled Glioma-Associated Macrophage via NEAT1/miR-125a/STAT3 Pathway
by Tong Pan, Dong-Kun Xie, Juan Li, Yu-Jie Qiang, Song-Yuan Fan, Ting-Ting Wang, Yuan-Yuan Han, Jian Zang, Yang Yang, Jun-Long Zhao, San-Zhong Li and Shuang Wu
Cancers 2024, 16(14), 2500; https://doi.org/10.3390/cancers16142500 - 9 Jul 2024
Viewed by 466
Abstract
Glioblastoma (GBM), as the most common primary brain tumor, usually results in an extremely poor prognosis, in which glioma stem cells (GSCs) and their immunosuppressive microenvironment prominently intervene in the resistance to radiotherapy and chemotherapy that directly leads to tumor recurrence and shortened [...] Read more.
Glioblastoma (GBM), as the most common primary brain tumor, usually results in an extremely poor prognosis, in which glioma stem cells (GSCs) and their immunosuppressive microenvironment prominently intervene in the resistance to radiotherapy and chemotherapy that directly leads to tumor recurrence and shortened survival time. The specific mechanism through which exosomes generated from GSCs support the creation of an immunosuppressive microenvironment remains unknown, while it is acknowledged to be engaged in intercellular communication and the regulation of the glioma immunosuppressive microenvironment. The elevated expression of LncRNA-NEAT1 was found in glioma cells after radiotherapy, chemotherapy, and DNA damage stimulation, and NEAT1 could promote the malignant biological activities of GSCs. Emerging evidence suggests that lncRNAs may reply to external stimuli or DNA damage by playing a role in modulating different aspects of tumor biology. Our study demonstrated a promotive role of the carried NEAT1 by GSC-derived exosomes in the polarization of M2-like macrophages. Further experiments demonstrated the mediative role of miR-125a and its target gene STAT3 in NEAT1-induced polarization of M2-like macrophages that promote glioma progression. Our findings elucidate the mechanism by which GSCs influence the polarization of M2-like macrophages through exosomes, which may contribute to the formation of immunosuppressive microenvironments. Taken together, our study reveals the miR-125a-STAT3 pathway through which exosomal NEAT1 from treatment-resistant GSCs contributes to M2-like macrophage polarization, indicating the potential of exosomal NEAT1 for treating glioma. Full article
(This article belongs to the Special Issue Novel Transcriptional Factors Regulating Cancer Stemness)
►▼ Show Figures

Figure 1

12 pages, 1045 KiB  
Article
Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies
by Felicitas Schulz, Paul Jäger, Johanna Tischer, Alessia Fraccaroli, Gesine Bug, Andreas Hausmann, Ben-Niklas Baermann, Patrick Tressin, Alexander Hoelscher, Annika Kasprzak, Kathrin Nachtkamp, Johannes Schetelig, Inken Hilgendorf, Ulrich Germing, Sascha Dietrich and Guido Kobbe
Cancers 2024, 16(3), 532; https://doi.org/10.3390/cancers16030532 - 26 Jan 2024
Cited by 2 | Viewed by 1471
Abstract
Up to 50% of patients with high-risk myeloid malignancies die of relapse after allogeneic stem cell transplantation. Current sequential conditioning regimens like the FLAMSA protocol combine intensive induction therapy with TBI or alkylators. Venetoclax has synergistic effects to chemotherapy. In a retrospective survey [...] Read more.
Up to 50% of patients with high-risk myeloid malignancies die of relapse after allogeneic stem cell transplantation. Current sequential conditioning regimens like the FLAMSA protocol combine intensive induction therapy with TBI or alkylators. Venetoclax has synergistic effects to chemotherapy. In a retrospective survey among German transplant centers, we identified 61 patients with myeloid malignancies that had received FLAMSA-based sequential conditioning with venetoclax between 2018 and 2022 as an individualized treatment approach. Sixty patients (98%) had active disease at transplant and 74% had genetic high-risk features. Patients received allografts from matched unrelated, matched related, or mismatched donors. Tumor lysis syndrome occurred in two patients but no significant non-hematologic toxicity related to venetoclax was observed. On day +30, 55 patients (90%) were in complete remission. Acute GvHD II°–IV° occurred in 17 (28%) and moderate/severe chronic GvHD in 7 patients (12%). Event-free survival and overall survival were 64% and 80% at 1 year as well as 57% and 75% at 2 years, respectively. The off-label combination of sequential FLAMSA-RIC with venetoclax appears to be safe and highly effective. To further validate these insights and enhance the idea of smart conditioning, a controlled prospective clinical trial was initiated in July 2023. Full article
(This article belongs to the Special Issue Novel Transcriptional Factors Regulating Cancer Stemness)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop